Adovate Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

Adovate General Information

Description

Operator of an adenosine drug development platform intended to create novel therapeutics targeting adenosine receptors involved in major diseases. The company specializes in designing patented compounds with favorable physicochemical characteristics and optimized distribution kinetics that overcome historical limitations of adenosine receptor-targeting drugs, enabling doctors to advance previously challenging therapeutic targets into viable treatment options.

Contact Information

Website
www.adovate.com
Formerly Known As
Adenomed
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1180 Seminole Trail
  • Suite 495
  • Charlottesville, VA 22901
  • United States
Primary Industry
Drug Discovery
Corporate Office
  • 1180 Seminole Trail
  • Suite 495
  • Charlottesville, VA 22901
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adovate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-Aug-2025 Completed Product Development
1. Accelerator/Incubator 15-May-2025 Completed Product Development
To view Adovate’s complete valuation and funding history, request access »

Adovate Patents

Adovate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022275564-A1 Cyclic amide-containing pyridyl xanthines as a 2b antagonists Pending 18-May-2021
CA-3218963-A1 Cyclic amide-containing pyridyl xanthines as a2b antagonists Pending 18-May-2021
US-11814387-B2 Cyclic amide-containing pyridyl xanthines as a2b antagonists Active 18-May-2021
US-12269828-B2 Cyclic amide-containing pyridyl xanthines as a2b antagonists Active 18-May-2021
US-20220402919-A1 Cyclic amide-containing pyridyl xanthines as a2b antagonists Active 18-May-2021 C07D473/06
To view Adovate’s complete patent history, request access »

Adovate Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adovate Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Blue Valley Fund One Venture Capital Minority
VentureSouth Angel Group Minority
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
Virginia Catalyst University
To view Adovate’s complete investors history, request access »

Adovate Acquisitions (1)

Adovate’s most recent deal was a Merger/Acquisition with Purnovate. The deal was made on 30-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Purnovate 30-Jun-2023 Merger/Acquisition Drug Discovery
To view Adovate’s complete acquisitions history, request access »

Adovate FAQs

  • When was Adovate founded?

    Adovate was founded in 2023.

  • Where is Adovate headquartered?

    Adovate is headquartered in Charlottesville, VA.

  • What is the size of Adovate?

    Adovate has 22 total employees.

  • What industry is Adovate in?

    Adovate’s primary industry is Drug Discovery.

  • Is Adovate a private or public company?

    Adovate is a Private company.

  • What is Adovate’s current revenue?

    The current revenue for Adovate is .

  • Who are Adovate’s investors?

    Blue Valley Fund One, VentureSouth, Johnson & Johnson Innovation - JLABS, and Virginia Catalyst have invested in Adovate.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process